The acquisition of fresh human tissue is often an impediment to significant research advances. As an alternative, Discovery Life Sciences offers cryopreserved human dissociated tumor cells and tissues as a viable specimen source for many downstream applications, including immunophenotyping, bulk and single-cell sequencing and single-cell functionality. Extensive cellular profiling of these samples by flow cytometry revealed indication-specific trends in the composition of the tumor microenvironment. Additionally, these specimens provide the opportunity to screen for novel biomarker expressions including the expression patterns of the programmed cell death protein-1/ programmed cell death ligand-1 (PD1/PDL1) pathway.
These dissociated tumor cells are amenable to the 10X Genomics single cell pipelines, and workflows have been established to optimize sample preparation into these assays. Finally, as viable cell suspensions, dissociated human tissues can be utilized in both short-term and long-term cultures, and the functionality of tumor-infiltrating T cells can be evaluated using IsoPlexis single-cell proteomics pipelines. Collectively, cryopreserved dissociated human tissue allows for multifaceted analysis of the next generation of cancer therapies.
Register to learn about the applications of cryopreserved human dissociated tumor cells (DTCs) for drug and diagnostic development.
Shawn Fahl, PhD, VP Lab Operations, Cell Services & R&D, Biospecimens, Discovery Life Sciences
Dr. Shawn Fahl is a skilled immunologist working to advance the cellular analytical pipelines and R&D laboratory processes for Discovery Life Sciences. Dr. Fahl received his PhD in microbiology from the University of Virginia in 2013 where he studied transcriptional control of B cell development. He continued his training as a postdoctoral fellow at Fox Chase Cancer Center from 2013-2017, where he focused on genomic regulation during gamma/delta T cell development. An expert in flow cytometric analyses evaluating lymphocyte biology, Dr. Fahl joined Discovery Life Sciences in June 2017 to advance the analytical workflows for many product lines, including dissociated tissue cells and isolated cell products from apheresis. As part of these efforts, Dr. Fahl has overseen the dissociation and flow cytometric analyses of over 4500 tissue samples and the implementation of single-cell genomics applications for dissociated tissue. Dr. Fahl has published numerous research articles in prominent scientific journals and presented at national and international conferences.
Who Should Attend?
Drug and diagnostic development scientists and R&D directors investigating new solutions for oncology treatments and testing
What You Will Learn
Attendees will learn about:
- Generation of cryopreserved dissociated tumor biobank for large scale biomarker discovery programs
- Optimization of workflows to achieve maximum utility from valuable tissue samples
- Evaluation of novel targets and biomarkers in solid tumor indications
- Establishment of in vitro culture systems to determine cellular responses to experimental drug compounds
Discovery Life Sciences
Discovery Life Sciences is the company of Biospecimen and Biomarker Specialists, combining the world’s largest commercial biospecimen inventory and procurement network with preeminent multi-omic biomarker service laboratories, including genomic, tissue biomarker, proteomic, and cell-based services to accelerate new therapies supported by biomarker and companion diagnostic programs for cancer, infectious disease, and other rare and complex conditions.
Through AllCells, our cell and gene therapy division, we offer one of the largest recallable donor pools, Research Use Only (RUO) and clinical-grade (GMP) fresh and cryopreserved human cellular materials to support cell and gene therapy programs at any scale from start to finish.
Driven by leading scientific expertise and innovative use of current technologies, the Discovery team engages and consults with customers to overcome obstacles more rapidly and obtain results to make critical research and development decisions at market-leading speed. We are Science at your Service™! For more information, visit dls.com.